Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Apellis Pharmaceuticals, Inc. - Common Stock
(NQ:
APLS
)
25.17
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apellis Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)
↗
July 18, 2025
Via
Benzinga
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
July 15, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals
↗
July 02, 2025
Via
Benzinga
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
July 01, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For May 7, 2025
↗
May 07, 2025
Via
Benzinga
Apellis Pharmaceuticals's Earnings Outlook
↗
May 06, 2025
Via
Benzinga
Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views
↗
March 03, 2025
Via
Benzinga
Earnings Scheduled For July 31, 2025
↗
July 31, 2025
Via
Benzinga
FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio
↗
July 29, 2025
FDA approves Apellis' Empaveli for rare kidney diseases, with trial data showing strong efficacy in reducing proteinuria and clearing C3 deposits.
Via
Benzinga
Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals
↗
July 28, 2025
The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial.
Via
Stocktwits
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
July 28, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
July 24, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
June 06, 2025
From
Apellis Pharmaceuticals, Inc.; Sobi
Via
GlobeNewswire
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
June 04, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts
↗
May 22, 2025
Via
Benzinga
Why Apellis Pharmaceuticals Wilted on Wednesday
↗
May 07, 2025
Via
The Motley Fool
Topics
Earnings
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
May 07, 2025
Via
Benzinga
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
May 07, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
May 06, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
April 30, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals
↗
April 29, 2025
Via
Benzinga
Apellis Announces Craig Wheeler to Join the Board of Directors
April 21, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
↗
April 01, 2025
Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.
Via
Benzinga
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
April 01, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre
↗
March 18, 2025
JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with over 94,000 doses delivered.
Via
Benzinga
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst
↗
March 05, 2025
JP Morgan sees Apellis' Syfovre as a potential $1.5B drug. Empaveli's approval for C3G/IC-MPGN could drive stock growth with a U.S. launch in 2H 2025.
Via
Benzinga
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
February 28, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For February 28, 2025
↗
February 28, 2025
Via
Benzinga
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
February 24, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
February 20, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
